Olumiant ® (baricitinib) tabletter

För fullständig produktresumé för Olumiant se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Olumiant® ▼ (baricitinib): Jämförelse av läkemedelsinteraktioner med Tofacitinib

Baricitinib och tofacitinib har inte studerats i någon i någon direkt jämförande klinisk prövning.

Baricitinib Drug-Drug Interaction Study Results

The recommended dose is 2 mg once daily in patients taking Organic Anion Transporter 3 (OAT3) inhibitors with a strong inhibition potential, such as probenecid.1

Tofacitinib Drug-Drug Interaction Study Results

From the Xeljanz® EU summary of product characteristics

The recommended dose is tofacitinib 5 mg once daily in patients with RA and receiving

- potent inhibitors of cytochrome P450 (CYP) 3A4, or

- 1 or more concomitant medicinal products that result in both moderate inhibition of CYP3A4 as well as potent inhibition of CYP2C19.2


Coadministration of tofacitinib with potent CYP inducers (e.g., rifampicin) may result in a loss of or reduced clinical response. Coadministration of potent inducers of CYP3A4 with tofacitinib is not recommended.

References

1. Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Xeljanz [summary of product characteristics]. Pfizer Europe MA EEIG

Glossary

BARI = baricitinib

CYP = cytochrome P450

OAT = organic anion transporter

RA = rheumatoid arthritis

US = United States

Xeljanz = Xeljanz® (tofacitinib)

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2019 M04 18


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss